Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 3/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.67 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | SCN1A | P35498 | 1/20 | 0.60 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.60 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.60 |
| ▸ | BCHE | P06276 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | ESR1 | P03372 | 5/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.56 |
| ▸ | DRD3 | P35462 | 2/20 | 0.56 |
| ▸ | HTR6 | P50406 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30969305 | 0.91 | EBP (0.56) | EBPSIGMAR1PARP10LMNASCN1A | |
| SCHEMBL30969207 | 0.89 | PARP10 (0.60) | EBPSIGMAR1PARP10LMNASCN1A | |
| SCHEMBL30969216 | 0.87 | EBP (0.55) | EBPSIGMAR1LMNASCN1ASCN2A | |
| SCHEMBL30969234 | 0.86 | PARP10 (0.61) | EBPSIGMAR1PARP10LMNASCN1A | |
| SCHEMBL30969221 | 0.86 | PARP10 (0.57) | EBPSIGMAR1PARP10BCHEACHE | |
| SCHEMBL21601503 | 0.86 | PARP10 (0.60) | EBPSIGMAR1PARP10KMT2A | |
| SCHEMBL250102 | 0.85 | EBP (0.69) | EBPSIGMAR1LMNASCN1ASCN2A | |
| SCHEMBL3149568 | 0.85 | EBP (0.69) | EBPSIGMAR1LMNASCN1ASCN2A | |
| SCHEMBL30969304 | 0.85 | THRA (0.61) | PARP10BCHEACHEESR1ESR2 | |
| SCHEMBL10885211 | 0.84 | EBP (0.71) | EBPSIGMAR1LMNASCN1ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063686-A1 | Carboxamide compounds and their use as antagonists of a human 11cby receptor | JOHNSON CHRISTOPHER NORBERT (GB) | 2004-04-01 | — | — | US | claimed |
| EP-1305304-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM PLC (GB) | 2003-05-02 | — | — | EP | claimed |
| WO-2002010146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-02-07 | — | — | WO | claimed |
| EP-4642766-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-11-05 | — | — | EP | disclosed |
| WO-2024145585-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-04 | — | — | WO | disclosed |
| EP-3275440-B1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | NAT CT GERIATRICS & GERONTOLOGY (JP) | 2022-05-04 | — | — | EP | disclosed |
| EP-3275440-A1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | National Center for Geriatrics and Gerontology (JP) | 2018-01-31 | — | — | EP | disclosed |
| US-20040063686-A1 | Carboxamide compounds and their use as antagonists of a human 11cby receptor | JOHNSON CHRISTOPHER NORBERT (GB) | 2004-04-01 | — | — | US | disclosed |
| EP-1305304-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM PLC (GB) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002010146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063686-A1 | Carboxamide compounds and their use as antagonists of a human 11cby receptor | CNR1, GPR3, CCKAR | EBP 1703/4885SIGMAR1 99/4885PARP10 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.